Why haven't we already bought Otezla?

Discussion in 'Pfizer' started by anonymous, Jul 1, 2019 at 8:03 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Take the $2 billion dollar cash cow, fire all their people, and plug it into our dermatology group until our pipeline matures. It would be nice to walk into an office or two where people actually liked my product.
     

  2. anonymous

    anonymous Guest

    Pipeline matures...right, because we are just an R&D machine! We stay profitable through purchasing other companies products because we can’t develop our own...
     
  3. anonymous

    anonymous Guest

    makes sense to me
     
  4. anonymous

    anonymous Guest

    Hate to break it to you, but its a billion + blockbuster BECAUSE OF THE PEOPLE. If we bought it, it would die off quickly.

    Even if we fired all of you and brought their people over to sell it, they would all leave once they realized what the Pfizer culture does to their souls.
     
  5. anonymous

    anonymous Guest

    Amgen was more proactive to shoring up their pipeline & beat Pfe to the punch.
    Pfe is still looking for products to replace Xeljanz in 48 months
     
  6. anonymous

    anonymous Guest

    Amgen will suffocate Otezla about as quickly as Pfizer would. What Celgene got, that big Pharma doesn't get is that if you actually PAY FOR PERFORMANCE instead of just TALKING AS IF YOU DO, then reps will sell a boat load of product x. Look at the Otezla PI. Product is a dog with fleas, yet they sell $3 billion of it even with horrible market access. Why? Because they pay for performance.
     
  7. anonymous

    anonymous Guest

    That is the truth. Big pharma wants to avoid the controversy (and possible big checks to OIG) so they dumb it down. Sad but true.
     
  8. anonymous

    anonymous Guest


    I was an Otezla rep. I left because the on-boarding was so onerous. They are a complete cluster. I know many top reps that are planning to leave in April for two reasons. First, that's the quickest retention payout. Second, the Otezla numbers are completely jacked up. They were good the first fews years but starting getting suspicious around 2017. Now, you have no idea how you do until they announce final rankings after the black out period. Completely destroyed faith in their system.
     
  9. anonymous

    anonymous Guest


    I have already adopted the Amgen way. I keep my head down and don't do anything.

    I plan to stay all year and collect all the retention payouts.

    Completely agree with the numbers garbage. Unless you are in Texas, Minnesota or California you aren't going to win a thing. Numbers mean nothing any more.
     
  10. anonymous

    anonymous Guest

    I&I tried but Amgen pushed price too high and out bidded Pfizer
     
  11. anonymous

    anonymous Guest

    o_O